eGFR-C

Important Message: COVID-19
We are now home-based during the COVID-19 pandemic but available and working. Responses may however take longer than normal as staff may be working altered hours but we are cross covering trials as required and urgent matters will be dealt with promptly. Please do not contact our usual office/landline number and instead email the trial contact and copy in the trial mailbox. If a query requires a prompt response please mark as ‘urgent’ in the email subject header.

The results of the eGFR-C biological variability study were published in July 2019 in Kidney International:

Ceri Rowe, Alice J. Sitch, Jonathan Barratt, Elizabeth A. Brettell, Paul Cockwell, R Neil Dalton, Jon J. Deeks, Gillian Eaglestone, Tracy Pellatt-Higgins, Philip A. Kalra, Kamlesh Khunti, Fiona C. Loud, Frances S. Morris, Ryan S. Ottridge, Paul E. Stevens, Claire C. Sharpe, Andrew J. Sutton, Maarten W. Taal, Edmund J. Lamb, on behalf of the e GFR-C study group. Biological variation of measured and estimated GFR in patients with chronic kidney disease. Kidney International, Volume 96, Issue 2, pages 429-435, August 2019, https://doi.org/10.1016/j.kint.2019.02.021.

Study details

Full Title: Accuracy of glomerular filtration rate (GFR) estimation using creatinine and cystatin C and albuminuria for monitoring disease progression in patients with stage 3 chronic kidney disease: prospective longitudinal study in a multi-ethnic population.

Short Title: eGFR-C.

Aims of the study: To estimate and compare the accuracy and precision of GFR-estimating equations based on the MDRD equation and three CKD-EPI equations using either creatinine or cystatin C or a combination of both in people with stage 3 CKD.

Study design: Multi-centre UK prospective longitudinal cohort study.

Sample size: 1249 participants were recruited over 35 months.

Study Duration: The accrual period lasted 35 months and all patients in the main study will be followed up for 3 years. The end of trial will be 6 months after the last data capture. The total study duration is 83 months.

Timeframes: NIHR HTA grant start date: 1st August 2013. Study set up took place in 6 months, recruitment lasted 35 months, all main study patients will be followed up for 36 months and 6 months has been allocated for data analysis and report writing (final results due end of June 2020).

______________________________________________________